User profiles for Michael Wendt

Michael K Wendt

Associate Professor of Pharmacology, Purdue University
Verified email at purdue.edu
Cited by 4858

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

…, CB Thompson, KJ Tomaselli, B Wang, MD Wendt… - Nature, 2005 - nature.com
Proteins in the Bcl-2 family are central regulators of programmed cell death 1 , and members
that inhibit apoptosis, such as Bcl-X L and Bcl-2, are overexpressed in many cancers and …

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

…, ML Smith, GM Sullivan, SK Tahir, C Tse, MD Wendt… - Nature medicine, 2013 - nature.com
Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic
process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance …

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

…, JM Tarrant, N La, L Wang, ZF Tao, MD Wendt… - Science translational …, 2015 - science.org
The BCL-2/BCL-X L /BCL-W inhibitor ABT-263 (navitoclax) has shown promising clinical activity
in lymphoid malignancies such as chronic lymphocytic leukemia. However, its efficacy in …

Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL

…, X Song, X Wang, MD Wendt… - Journal of medicinal …, 2007 - ACS Publications
Overexpression of the antiapototic proteins Bcl-2 and Bcl-xL provides a common mechanism
through which cancer cells gain a survival advantage and become resistant to conventional …

Mechanisms of the epithelial–mesenchymal transition by TGF-β

MK Wendt, TM Allington, WP Schiemann - Future Oncology, 2009 - Future Medicine
The formation of epithelial cell barriers results from the defined spatiotemporal differentiation
of stem cells into a specialized and polarized epithelium, a process termed mesenchymal–…

Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins

…, SK Tahir, C Tse, X Wang, MD Wendt… - Journal of medicinal …, 2008 - ACS Publications
Overexpression of prosurvival proteins such as Bcl-2 and Bcl-X L has been correlated with
tumorigenesis and resistance to chemotherapy, and thus, the development of antagonists of …

Phosphoproteins in extracellular vesicles as candidate markers for breast cancer

…, L Pan, H Andaluz, MK Wendt… - Proceedings of the …, 2017 - National Acad Sciences
The state of protein phosphorylation can be a key determinant of cellular physiology such
as early-stage cancer, but the development of phosphoproteins in biofluids for disease …

Beyond the rule of 5: lessons learned from AbbVie's drugs and compound collection: miniperspective

…, HJ Chen, PB Cox, MD Wendt - Journal of medicinal …, 2017 - ACS Publications
Recently, there has been an increasing focus on the pursuit of targets considered to be less
druggable that offer potential for development of promising new therapeutic agents for the …

Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression

MK Wendt, M Tian, WP Schiemann - Cell and tissue research, 2012 - Springer
Transforming growth factor-β (TGF-β) is a potent pleiotropic cytokine that regulates mammalian
development, differentiation, and homeostasis in essentially all cell types and tissues. …

Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer

MK Wendt, MA Taylor, BJ Schiemann… - Molecular biology of …, 2011 - Am Soc Cell Biol
Reduced epithelial cadherin (E-cad) is a hallmark of invasive carcinomas that have acquired
epithelial-mesenchymal transition (EMT) phenotypes. Here we show that down-regulated E-…